ZenaTech Zooms on Hegseth Directive
ZenaTech, Inc. (NASDAQ: ZENA), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today reacts to the July 10, 2025 new policy directive from Secretary of Defense Pete Hegseth, ‘Unleashing U.S. Military Drone Dominance.’ ZenaTech confirms that under this policy directive, its entire portfolio of ZenaDrone drones qualify as Group 1–2 expendable assets and are now enabled for direct purchases by field commanders for both training and real-world missions, and they no longer need Green or Blue UAS (Unmanned Aerial System) certification.The policy directive, in which he called drones “the biggest battlefield innovation in a generation,” mandates the rapid acquisition, deployment, and operational use of small, low-cost Group 1 and 2 drones. The directive now treats them as expendable commodities rather than durable assets, which the Company anticipates will streamline bureaucracy, encourage innovation including the use of prototypes and commercial off-the-shelf systems, to ensure the U.S. military can outpace adversaries by rapidly scaling drone capabilities on the battlefield. This memo also marks a paradigm shift, placing battlefield acquisition authority in the hands of frontline commanders, not procurement offices.ZENA shares faltered 73 cents, or 17.2%, to $4.94 Friday.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


